DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INDEX (Page number shown is first page of article in which entry is indexed.) Acetaminophen, 418 Barbiturates, breakdown of cytochrome P-450 heme Acetanilide, 418 by, 275 Acetanilide hydroxylation, 191 Benzo[a]pyrene hydroxylation by aryl hydrocarbon effect of metyrapone and analogs on, 184 hydroxylase, 386 Acetone, effects on electron paramagnetic resonance Benzpyrene hydroxylase, 380 signals, 231 Benzpyrene metabolism in control and induced rats Acetophenetidin, effect of analgesics and cigarette and mice, 380 smoke on metabolism of, 211 Biliary excretion, effects of phenobarbital in man, 424 N-acetyl-p-aminophenol, effect of analgesics and Bilirubin, effect of ethanol on, 428 cigarette smoke on metabolism from acetopheneti- Blood flow, liver, to determine drug half-lives, 411 din, 211 Active centers of hepatic microsomal cytochrome P-450, 194 Carbanions, formation and binding by cytochrome Active site of cytochrome P-450, I P-450, 176 Adjuvant-induced arthritis in rat, impaired drug Carbon disulfide, loss of cytochrome P-450 by, 267 metabolism in, 251 Carbon monoxide, 191 ah locus, association with drug-metabolizing enzymes, binding activation energies, I 231 binding rate constants, I Albumin, transfer from cytochrome P-420 in metab- effect on N-oxidation, 299 olism of cytochrome P-450, 293 production, 286 Alcohol dehydrogenase, differentiation from micro- specific carrier in lung and placenta, 374 somal ethanol-oxidizing system, 428 Carcinogen metabolism, induction in skin in tissue Alkyl hydroperoxides, 92 culture, 386 Allopurinol, inhibition of drug metabolism after, 402 Catabolism Allylisopropylacetamide, 259, 286 heme, 286 2-Allyl-2-isopropylacetamide, loss of cytochrome hemoprotein, 286 P-450 by, 267 Catalase Amines differentiation from microsomal ethanol-oxidizing individual, N-oxidation of, 299 system, 428 primary, deamination of, 337 role in hepatic microsomal ethanol oxidation, 441 Amino acyl tRNA synthetase activity, 239 Chlorinated hydrocarbons, carbanion formation by re- p-Aminobenzoic acid, 259 duction of, 176 Amino carbinol oxidation, 322 Cholestasis, effect of phenobarbital on, 424 5-Aminolevulinate synthetase activity, relation of loss Cholesterol of heme to, 267 content of lung and liver microsomes, 358 Aminolevulinic acid, 259 metabolism, effects of ethanol on, 428 Aminotriazole, 259 Cigarette smoke, effect on acetophenetidin metabolism, Amphetamine deamination, phenylacetone oxime in, 211 332 Cobaltous chloride, 259 Analgesics, effect on acetophenetidin metabolism, 211 Cortisol, to determine drug half-lives, 411 Aniline hydroxylation, 191 Cortisone acetate, effect on drug metabolism, 216 Antituberculous drugs, effect on cytochrome P-450 con- Covalent binding, 418 tent and hydroxylating enzyme system, 224 Cyanide, effects on drug oxidation, 139 Arthritis, adjuvant-induced, in rat: impaired drug Cytochrome b,, 129 metabolism in, 251 electron transfer mediated by, 150 Arylamines, N-oxidation, 314 Cytochrome P-420 Aryl hydrocarbon benzo[a]pyrene hydroxylase, 231 characterization, 45 Aryl hydrocarbon hydroxylase, induction in human differences in ‘untreated and 3-methylcholanthrene- skin in tissue culture, 386 treated rats, 40 Azo reduction, type II substrate oxidation and, en- transfer to albumin in metabolism of cytochrome hancement by metyrapone, 191 P-450, 293 483 484 IN DEX Cytochrome P-448 Electron paramagnetic resonance, to probe spin state effect on substrate specificity, 29 of iron, 45 extinction coefficient, 29 Endocrine systems, chemistry of cytochrome P-450 phospholipid content, 29 from, 21 purification, 29 Endoplasmic reticulum, synthesis and degradation of spectrum, 29 membrane proteins in, 84 Cytochrome P-450 Endoplasmic reticulum membranes, dynamic organ- anomalous properties, 6 ization of, 66 chemistry, from endocrine systems, 21 Enzyme inducers, effect on substrate specificity, 199 destruction, drug-induced, 267 Enzyme proteins, turnover in microsomal membrane, 80 effect on substrate specificity, 29 Enzyme-substrate complex, 111 enzyme systems, mechanism, 164 Ethanol metabolism, oxidative and peroxidative extinction coefficient, 29 mechanisms, 449 free hepatic polyribosomes and, 62 Ethanol oxidation genetic differences, 231 hepatic microsomal, role of hydrogen peroxide and heme, breakdown by barbiturates, 275 catalase in, 441 hydrophobic region, 6 hepatic microsomal, significance and characteriza- mechanism of action, 92 tion, 428 molecular function, 98 NADPH-cytochrome c reductase in, 455 NADPH-cytochrome c reductase and, 121 Ethylmorphine, spectral changes, 129 N-oxidation of amines, 299 Ethylmorphine N-demethylation, effect of steroids on, optical and magnetic probes of, 45 216 oxygenated, 129 Extinction coefficient of cytochromes P-450 and P-448, partial purification, 6 29 phospholipid content, 29 Extrahepatic drug metabolism, effects of hepatic in- placental, role in oxygen diffusion, 368 ducers and inhibitors on, 342 purification, 29 Extrahepatic microsomal N-oxidation, 299 reductase, 380 Extrahepatic mono-oxygenase system, 350 solubilized, 156 spectrum, 6, 29 Flavoprotein-catalyzed N-oxidation, 314 substrate complexes, I I I Fluorene, interaction with cytochrome P-450, 176 Cytochrome P”450cam, Furosemide, 418 DDT and benzpyrene as inducers in rats and mice, 380 Deamination, microsomal, heavy isotope studies, 337 Genetic differences in cytochrome P.450, 231 Degradation of microsomal hemoproteins, 256 Glucose metabolism, effects of ethanol on, 428 Dehydrogenase, microsomal, 322 Glutathione, 418 Dehydrogenation of 2-hydroxymedazepam, 322 Glycine conjugation, 259 Desmethylimipramine metabolism, interindividual differences, 469 Heavy isotope studies of microsomal deamination, 337 Detergent(s) Heme catabolism, 286 effects on electron paramagnetic resonance signals, Heme oxygenase, 286 231 Heme synthesis, 259 treatment of microsomes, 74 Heme transfer, implication in metabolism of cyto- Diazepam, from oxidation of 2-hydroxymedazepam, chrome P-450, 293 322 Hemoglobin binding by lung microsomes, 358 3, 5-Diethoxycarbonyl-l , 4-dihydro-2 , 4 , 6-trimethyl- emolysis, 418 pyridine, 259 Heterogeneity of cytochrome P.450 in vicinity of heme, Dimethylaniline, N-oxidation of, 314 45 Dioxymethylene compounds as ligands for cytochrome Hexobarbital, spectral changes, 129 P-450, 176 Hexobarbital hydroxylation, effect of steroids on, 216 Diphenylhydantoin metabolism, interindividual dif- Hydrogen peroxide, role in hepatic microsomal ethanol ferences, 469 oxidation, 441 Disulfiram, inhibition of drug metabolism after, 402 Hydroperoxides, 92 i-Dopa, inhibition of drug metabolism after, 402 Hydrophobic region of cytochrome P-450, 6 DPNH synergism of TPNH-dependent mixed function Hydroxylase, microsomal, unspecific, induction in hu- oxidase reactions, 139 man liver, 224 Dynamic organization of endoplasmic reticulum mem- II 3-Hydroxylase of adrenocortical mitochondria, cy- branes, 66 tochrome P-450 function and, 21 INDEX 485 Hydroxylation, drug, 92 Mixed function oxidations, 129 2-Hydroxymedazepam, oxidation, 322 Molecular function of cytochrome P-450, 98 Hyperlipemia from ethanol, 428 Molecular size-turnover correlation of membrane proteins, 84 Induction of cytochrome P450 reductase by pheno- Molecular weight of solubilized cytochrome P-450, 156 barbital vs. 3-methylcholanthrene, 380 Mononuclear ferric iron, probes of spin state in oxi- Inelastic light-scattering studies of phospholipids, 74 dized cytochrome P450, 45 Inhibition of drug metabolism, 164, 402 Mono-oxygenase induction, genetic differences in cy- Inhibitors tochrome P450 during, 231 and inducers, liver and kidney cortex compared, 350 Mono-oxygenase system, rat kidney cortex, 350 effects on N-oxidation, 299 M#{246}ssbauerparameters of cytochrome P4SOcam, of drug metabolism, 162 Mutual depletion system kinetics, 194 Initiation factor activity after 3-methylcholanthrene NAD-dependent microsomal dehydrogenase, 322 and -naphthoflavone, 239 Interindividual differences NADH oxidation, relation to NADPH oxidation, ISO in drug metabolism in man, 469 NADPH, formation of microsomal hydrogen peroxide in drug oxidation in man, 411 from, 441 Ionic strength, effects on cytochrome P450 reductase, NADPH-cytochrome c reductase, 92 380 microsomal oxidation of ethanol and methanol, 455 Isosafrole, effect on extrahepatic drug metabolism, 342 role in microsomal reactions, 121 NADPH-cytochrome P-450 reductase, 92 Ligands NADPH oxidations, relation to NADH oxidation, 150 carbanions as, 176 -Naphthoflavone, initiation factor after, 239 cytochrome P’4SOcam, 2-Naphthylamine, N-oxidation of, 314 Lipid peroxidation, 286 Necrosis, liver, 418 Lung, oxygen and carbon monoxide carrier in, 374 Neoprontosil reduction, 191 Lung microsomes, relation to drug metabolism, 358 2-Nitropropane, ligand binding of, 176 Nonmercaptide ligand, variable, in oxidized hemo- M, factor, 239 protein, 45 Nonsubstrates, interaction with flavoprotein oxidase, M, + M, factor, 239 Magnetic probe of cytochrome P-450’s, 45 314 Membrane proteins, synthesis and degradation of, 84 Nortriptyline, inhibition of drug metabolism after, 402 Membranes, enzyme turnover in, 80 Nortriptiline metabolism, interindividual differences, Mercaptide ligand, fixed, in oxidized hemoprotein, 45 469 Messenger RN A-polyribosome-cytochrome P-450 com- Novaminsulfonum, effect on drug metabolism, 224 plex, 62 N-oxidation of arylamines, 314 Messenger RNA’s, effect of phenobarbital on, 248 N-oxidation of individual amines, cytochrome P.450 Metal ion effects on cytochrome P-450 reductase, 380 role, 299 Methanol oxidation, NADPH-cytochrome
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
  • Glycoprotein Biosynthesis Carol Lambadarios, Cetra Hastings, J

    Glycoprotein Biosynthesis Carol Lambadarios, Cetra Hastings, J

    Steroid effects on human endometrial glycoprotein biosynthesis Carol Lambadarios, Cetra Hastings, J. Abo-Darub and I. D. Cooke Department of Obstetrics and Gynaecology, University of Sheffield, Jessop Hospitalfor Women, Leavygreave Road, Sheffield 53 IRE, U.K. Summary. Human endometrium from the secretory phase of the menstrual cycle was incubated with 3H- and 14C-labelled glucosamine and [3H]leucine. Incorporation into secreted extracellular glycoprotein and accumulation of the label into the micro- somal fraction were measured. When oestradiol or progesterone were added to the medium, medroxyprogesterone acetate (MPA), ethynodiol diacetate and chlormadi- none acetate reduced incorporation of glucosamine and MPA reduced incorporation of leucine into glycoprotein. MPA reduced the amount of glucosamine in the micro- somal fraction and also had an effect on amino acid transport within the endometrial cells, as indicated by intracellular \g=m\-aminoisobutyricacid space measurements. These results and the ratios of 3H and 14C in the microsomal fraction and secreted protein suggest that MPA has a primary effect in decreasing amino sugar incorporation and a secondary effect in reducing amino acid incorporation into glycoprotein. Introduction The histology of human endometrial glandular cell secretion has been described by Noyes, Hertig & Rock (1950). During the secretory phase the Golgi complexes are greatly developed and the distended endoplasmic reticulum contains glycogen and glycoprotein (Wynn & Harris, 1967; Wynn & Woolley, 1967). Pincus, Rock & Garcia (1958) reported alterations in endometrial histology in response to synthetic progestagens. Flowers, Wilborn & Enger (1974) studied the ultrastructure of the endometrium after treatment with quingestanol acetate for 3 months and observed that many aspects of protein synthesis were affected and that, despite ovulation, subnuclear vacuolation did not occur.
  • Studies of Cancer in Experimental Animals

    Studies of Cancer in Experimental Animals

    ORAL CONTRACEPTIVES, COMBINED 201 3. Studies of Cancer in Experimental Animals In this section, only relevant studies on oestrogens and progestogens alone and in combination that were published subsequent to or not included in Volume 21 of the IARC Monographs (IARC, 1979) are reviewed in detail. Studies reviewed previously are summarized briefly. 3.1 Oestrogen–progestogen combinations 3.1.1 Studies reviewed previously Mouse The results of studies reviewed previously (Committee on Safety of Medicines, 1972; IARC, 1979) on the carcinogenicity of combinations of oestrogens and proges- togens in mice are as follows: Chlormadinone acetate in combination with mestranol tested by oral administration to mice caused an increased incidence of pituitary adenomas in animals of each sex. Oral administration of chlormadinone acetate in combination with ethinyloestradiol to mice resulted in an increased incidence of mammary tumours in intact and castrated males. After oral administration of ethynodiol diacetate and mestranol to mice, increased incidences of pituitary adenomas were observed in animals of each sex. The combination of ethynodiol diacetate plus ethinyloestradiol, tested by oral administration to mice, increased the incidences of pituitary adenomas in animals of each sex and of malignant tumours of connective tissues of the uterus. Lynoestrenol in combination with mestranol was tested in mice by oral administration. A slight, nonsignificant increase in the incidence of malignant mammary tumours was observed in females which was greater than that caused by lynoestrenol or mestranol alone. The combination of megestrol acetate plus ethinyloestradiol, tested by oral adminis- tration to mice, caused an increased incidence of malignant mammary tumours in animals of each sex.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Annex 2. Preparations of Oestrogens, Progestogens and Combinations of Oestrogens and Progestogens That Are Or Have Been Used As

    Annex 2. Preparations of Oestrogens, Progestogens and Combinations of Oestrogens and Progestogens That Are Or Have Been Used As

    Annex 2. Preparations of oestrogens, progestogens and combinations of oestrogens and progestogens that are or have been used as hormonal contraceptives and for post-menopausal hormonal therapy, with known trade names Table 1. Some combinations of oestrogens and progestogens used in oral contraceptives, with known trade names Combination Trade names Oestrogen Dose Progestogen Dose (μg) (mg) Ethinyloestradiol Biphasic 50 Chlormadinone acetate 1/2 Neo-Eunomin Monophasic 35 Cyproterone acetate 2 Diane, Diane-35, Diane-Mite, Diane Nova, Dianette, Gynofen 35 Monophasic 20 Desogestrel 0.15 Cycléane-20, Lovelle, Marvelon 20, Mercilon, Microdosis, Myralon, Securgin, Segurin ANNEX 2 Monophasic 30 Desogestrel 0.15 Cycléane-30, Desogen, Desolett, Frilavon, Marvelon, Marvelon 30, Marviol, Microdiol, Novelon, Ortho-Cept, Planum, Practil, Prevenon, Varnoline Biphasic 40/30 Desogestrel 0.025/0.125 Gracial Biphasic 50 Desogestrel 0/0.125 Ovidol, Oviol Triphasic 35/30 Desogestrel 0.05/0.1/0.15 Trimiron Monophasic 30 Dienogest 2 Valette Monophasic 20 Gestodene 0.075 Harmonet, Meliane Monophasic 30 Gestodene 0.075 Ciclomex, Evacin, Femodeen, Femoden, Femodene, Femovan, Ginera, Ginoden, Gynera, Gynovin, Minulet, Minulette, Moneva, Myvlar Triphasic 30/40/30 Gestodene 0.05/0.07/0.1 Milvane, Phaeva, Triadene, Tricilomex, Tri- Femoden, Trigynera, Tri-Gynera, Trigynovin, Triminulet, Triodeen, Trioden, Triodena, Triodene Monophasic 20 Levonorgestrel 0.1 Miranova Minisiston, Monostep Monophasic 30 Levonorgestrel 0.125 615 616 Table 1 (contd) Combination Trade names
  • Pros and Cons Controversy on Molecular Imaging and Dynamic

    Pros and Cons Controversy on Molecular Imaging and Dynamic

    Open Access Archives of Biotechnology and Biomedicine Research Article Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- ISSN Standard DNA/RNA of Human Preserving 2639-6777 Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Address for Correspondence: Dr. Alireza Abstract Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, In the current study, we have investigated pros and cons controversy on molecular imaging and dynamics USA, Email: of double-standard DNA/RNA of human preserving stem cells-binding Nano molecules with Androgens/ [email protected]; Anabolic Steroids (AAS) or Testosterone derivatives through tracking of Helium-4 nucleus (Alpha particle) using [email protected] synchrotron radiation. In this regard, the enzymatic oxidation of double-standard DNA/RNA of human preserving Submitted: 31 October 2017 stem cells-binding Nano molecules by haem peroxidases (or heme peroxidases) such as Horseradish Peroxidase Approved: 13 November 2017 (HPR), Chloroperoxidase (CPO), Lactoperoxidase (LPO) and Lignin Peroxidase (LiP) is an important process from Published: 15 November 2017 both the synthetic and mechanistic point of view. Copyright: 2017 Heidari A. This is an open access article distributed under the Creative
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • RR-17: Scoping Review of Prenatal

    RR-17: Scoping Review of Prenatal

    NTP RESEARCH REPOrt ON THE SCOPING REVIEW OF PRENATAL EXPOSURE TO PROGESTOGENS AND ADVERSE HEALTH OUTCOMES NTP RR 17 SEPTEMBER 2020 NTP Research Report on the Scoping Review of Prenatal Exposure to Progestogens and Adverse Health Outcomes Research Report 17 September 2020 National Toxicology Program Public Health Service U.S. Department of Health and Human Services ISSN: 2473-4756 Research Triangle Park, North Carolina, USA Scoping Review of Prenatal Exposure to Progestogens and Adverse Health Outcomes Foreword The National Toxicology Program (NTP), established in 1978, is an interagency program within the Public Health Service of the U.S. Department of Health and Human Services. Its activities are executed through a partnership of the National Institute for Occupational Safety and Health (part of the Centers for Disease Control and Prevention), the Food and Drug Administration (primarily at the National Center for Toxicological Research), and the National Institute of Environmental Health Sciences (part of the National Institutes of Health), where the program is administratively located. NTP offers a unique venue for the testing, research, and analysis of agents of concern to identify toxic and biological effects, provide information that strengthens the science base, and inform decisions by health regulatory and research agencies to safeguard public health. NTP also works to develop and apply new and improved methods and approaches that advance toxicology and better assess health effects from environmental exposures. NTP reports the findings from many of its studies in the NTP Technical Report and Monograph series. NTP uses the Research Report series, which began in 2016, to report on work that does not fit readily into one of those two series, such as pilot studies, assay development or optimization studies, literature surveys or scoping reviews, and handbooks on NTP procedures or study specifications.
  • Ovulation Inhibition Doses of Progestins

    Ovulation Inhibition Doses of Progestins

    Contraception 84 (2011) 549–557 Review article Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide☆ ⁎ Jan Endrikata,b, , Christoph Gerlingera, Stephanie Richardc, Peter Rosenbaumb, Bernd Düsterberga aBayer Schering Pharma, Müllerstr. 178, D-13342 Berlin, Germany bUniversitätskliniken des Saarlandes, Frauenklinik, 66421 Homburg/Saar, Germany cUniversité de Montréal, Faculté de pharmacie, 2900, Boulevard Édouard-Montpetit Pavillon Roger-Gaudry, H-401, Montréal, Québec, Canada H3T 1J4 Received 16 September 2010; revised 25 March 2011; accepted 13 April 2011 Abstract Background: The objective of this analysis was to provide a comprehensive review of ovulation inhibition data of progestins currently available worldwide. This analysis may serve as a reference tool for research on new progestin molecules. Study Design: We used literature search engines to detect data of progestin monotherapies on ovulation inhibition in humans. Only treatments with stable dosing during a cycle were accepted. In a second step, we tried to estimate the 99% ovulation inhibiting doses and their fiducial confidence limits using the probit dose–response model. Finally, we analyzed the progestin doses of combined oral contraceptives currently on the market. Results: We found original data on 29 marketed and nonmarketed progestins in a total of 60 publications, published between 1956 and May 2010. Details on methods used for determining ovulation, number of doses and daily dose of each tested progestin, number of subjects, cycles and ovulations are summarized in a table. We designed one example of a dose–response curve using the statistical model. For most progestins, literature data were insufficient for this purpose.
  • Oral Contraceptives, Combined

    Oral Contraceptives, Combined

    ORAL CONTRACEPTIVES, COMBINED 1. Exposure Combined oral contraceptives consist of the steroid hormone oestrogen in combi- nation with a progestogen, taken primarily to prevent pregnancy. The same hormones can also be used in other forms for contraception. Combined oral contraceptive pills generally refer to pills in which an oestrogen and a progestogen are given concurrently in a monthly cycle. In contrast, a cycle of sequential oral contraceptive pills includes oestrogen-only pills followed by five to seven days of oestrogen plus progestogen pills. Sequential oral contraceptive pills were removed from the consumer market in the late 1970s; they are covered in an IARC monograph (IARC, 1979, 1987). Combined oral contraceptives are thus usually administered as a pill containing oestrogen and progestogen, which is taken daily for 20–22 days, followed by a seven-day pill-free interval (or seven days of placebo), during which time a withdrawal bleed is expected to occur. The most commonly used oestrogen is ethinyloestradiol, although mestranol is used in some formulations. The pro- gestogens most commonly used in combined oral contraceptives are derived from 19-nor- testosterone and include norethisterone, norgestrel and levonorgestrel, although many others are available (Kleinman, 1990) (see Annex 2, Table 1). Chemical and physical data and information on the synthesis, production, use and regulations and guidelines for hormones used in combined oral contraceptives are given in Annex 1. Annex 2 (Table 1) lists the trade names of many contemporary combined oral contraceptives with their formulations. Combined oral contraceptives are currently available in monophasic, biphasic and triphasic preparations, the terms referring to the number of different doses of progestogen they contain.
  • Index Vol. 16-23

    Index Vol. 16-23

    233 Index Vol. 16-23 The references of the Subject Index are given in the language of the respective contribution. Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgeftihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. A 17 Abortion, therapeutic 457,460 23 Acetylsalicylic acid (Aspirin®) 114 20 Academic research 169 16 O-Acetylserin-Sulfhydrylase A 390 18 Acanthocheilonema perstans 142 17 Acetylstrophanthidin 35 18 Acanthocheilonema streptocerca 142 22 Achromycin® (tetracycline) 53 22 Acaprin® (quinuronium sulfate) 42 19 Acidosis 529 20 Acebutolol 33, 36, 229 18 Acid phosphotase 66 18 Acedapson (Hansolar®, 4',4"'-sulfonylbis­ 16 Aconitase-Isomerase 436 acetanilide) 108, 156 17 Aconitine 35,46 17 Acedist® (bromfenofos, Ph 1882) 113, 134, 17 Acranil 119, 152 278 17 Acrichine® (quinacrine) 119 18 Aceperone 437 17 Acridine 295 16 Acetacetat-Decarboxylase 414 16 Acriftavin 100 17 2-Acetamido-5-nitrothiazole 261 17 Acrolein 358 17 Acetanilide 23, 497 18 Acronine 440 20 Acetanilide 400 21 Acrosin 366 23 Acetanilide 212 21 Acrylamide 186 20 Acetazolamide (Diamox®) 209,417 17 Actamer® (bithionol) 114,297 21 - 114 22 Actamer® (bithionol) 46 22 Acetohexamide (Dymelor®) 81 16 Actinomycin I 298 17 Acetohydroxamic acid 348 16 Actinomycin IV 298 17 Acetone 13, 17 16 Actinomycin V 298 16 Acetophenone 260 17 Actinomycin C, (actinomycin D) 376 17 2-Acetoxy-4' -chloro-3,5-diiodobenzanilide 16 Actinomycin D (actinomycin C" (clioxanide) 114,135,164,277,281
  • Methods of Contraception Verfahren Zur Empfängnisverhütung Methodes De Contraception

    Methods of Contraception Verfahren Zur Empfängnisverhütung Methodes De Contraception

    Europäisches Patentamt *EP000792152B1* (19) European Patent Office Office européen des brevets (11) EP 0 792 152 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 31/565, A61P 15/18, of the grant of the patent: A61P 15/00 14.04.2004 Bulletin 2004/16 // (A61K31/565, 31:565) (21) Application number: 95940773.5 (86) International application number: PCT/US1995/015131 (22) Date of filing: 21.11.1995 (87) International publication number: WO 1996/015794 (30.05.1996 Gazette 1996/25) (54) METHODS OF CONTRACEPTION VERFAHREN ZUR EMPFÄNGNISVERHÜTUNG METHODES DE CONTRACEPTION (84) Designated Contracting States: (56) References cited: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL EP-A- 0 659 432 WO-A-93/21926 PT SE WO-A-93/21927 WO-A-95/17194 WO-A-95/26730 (30) Priority: 22.11.1994 US 343383 • GUIAN CHEN, JUN RONG HUANG, JAMES (43) Date of publication of application: MAZELLA, LINDA TSENG: "Long-term effects of 03.09.1997 Bulletin 1997/36 progestin and RU 486 on prolactin and synthesis in human endometrial stromal cells" HUMAN (73) Proprietor: BALANCE PHARMACEUTICALS, INC. REPRODUCTION, vol. 4, no. 4, 1989, pages Pacific Palisades, CA 90272 (US) 355-358, XP000944177 • FERTILITY AND STERILITY, Vol. 53, No. 4, (72) Inventors: issued April 1990, KEKKONEN R. et al., • SPICER, Darcy V. "Interference With Ovulation by Sequential Pasadena, CA 91103 (US) Treatment With the Antiprogesterone RU486 and • PIKE, Malcolm Cecil Synthetic Progestin", pages 747-750, Long Beach, CA 90803 (US) XP000569448 • DANIELS, John R.